Sanofi and Regeneron, seeking to shield Dupixent, lose first IPR try against Amgen

5th October 2017 Uncategorised 0

To defend against Amgen’s claim that Sanofi and Regeneron had infringed one of its patents with new atopic dermatitis rollout Dupixent, the development partners went the inter partes review route to try to invalidate the patent in question. And so far, that effort has come up empty.

More: Sanofi and Regeneron, seeking to shield Dupixent, lose first IPR try against Amgen
Source: fierce